21st Austria weekly - Marinomed 22/05/2024 [pic1]Marinomed: Biotech AG VSE:MARI announces revenues of EUR 0.7 million recorded in the first quarter 2024. After observing record from Carragelose product sales heavily influenced by SARS-CoV-2 pandemic over past years revenue 2024 has declined to levels observed before pandemic. This decline is mostly due high inventories and return seasonality causing a drop customer demand. Due cost-conscious cash management equivalents stood at 1.9 compared 2.6 end 2023. The operating result EBIT -1.9 Q1 2023: -1.4 million loss for period amounted -2.1 million. “Although we are making constant progress working on several initiatives parallel situation remains challenging. Revenues
EQS-News: Marinomed Biotech AG / Announcement of the Convening of the General Meeting
Marinomed Biotech AG: Invitation to the 7th Annual General Meeting on Thursday, June 20,.
EQS-News: Marinomed Biotech AG / Key word: Quarter Results
Marinomed Biotech AG announces results for the first quarter of 2024
22.05.2024 / 07:45 CET/CEST
The issuer.